Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions.

ABSTRACT: Current recommendations for the use of intravenous iron therapy in the management of anaemia in patients with chronic kidney disease (CKD) are based on limited clinical evidence. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anaemia in Chronic Kidney Disease in 2012, a number of randomized clinical trials [notably, the Ferinject Assessment in Patients with Iron Deficiency Anaemia (FIND-CKD) and Randomized Trial to Evaluate IV and Oral Iron in Chronic Kidney Disease (REVOKE) trials] and observational studies have been completed, and a further large clinical trial-Proactive IV Iron Therapy in Dialysis Patients (PIVOTAL)-is currently underway. In this article, the implications of the findings from these recent studies are discus

SUBMITTER: Macdougall IC 

PROVIDER: S-EPMC5716151 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature